[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345500-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345500-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","isatin-mediated-inhibition-of-the-pi3kaktemt-signaling-axis-confers-antitumor-efficacy-in-ehrlich-solid-carcinoma-bearing-mice","Isatin-mediated inhibition of the PI3K/AKT/EMT signaling axis confers antitumor efficacy in Ehrlich solid carcinoma-bearing mice","","Despite advances, detailed insight into cancer’s biological mechanisms remains needed. Isatin, an indole-1 H-2,3-dione, is an attractive agent for new drug discovery. Here, the anticancer efficacy and potential toxicity of isatin in combination with doxorubicin in a mouse Ehrlich solid carcinoma model were examined by modulating the PI3K/AKT/EMT pathway. Combined treatment reduced tumor growth by 51%, increased necrosis, suppressed HIF-1α, NF-κB, PI3K, AKT, MMP2 and MMP9, increased IL-10 and decreased IL-6, and improved EMT marker profiles.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/isatin-mediated-inhibition-of-the-pi3kaktemt-signaling-axis-confers-antitumor-efficacy-in-ehrlich-solid-carcinoma-bearing-mice/345500/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/isatin-mediated-inhibition-of-the-pi3kaktemt-signaling-axis-confers-antitumor-efficacy-in-ehrlich-solid-carcinoma-bearing-mice/345500.png","ImageObject",300,407,{"name":42,"@type":43},"Levi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What cancer model was used to test isatin and doxorubicin?","Question",{"text":63,"@type":64},"The study used Ehrlich solid carcinoma-bearing mice (ESC model) to evaluate anticancer efficacy after tumor formation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the isatin–doxorubicin combination affect tumor outcomes?",{"text":68,"@type":64},"Compared with the positive control, the combined treatment reduced tumor growth by 51% and increased the amount of necrotic tissue.",{"name":70,"@type":61,"acceptedAnswer":71},"Which signaling and EMT-related markers were monitored, and what changed?",{"text":72,"@type":64},"The work assessed PI3K/AKT/EMT pathway components and EMT markers, reporting reduced HIF-1α, NF-κB, PI3K, AKT, MMP2, MMP9 and lower vimentin with elevated E-cadherin, consistent with EMT suppression.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345500,1791187413,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Effat etal. BMC Cancer (2026) 26:692 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-16247-0](https://doi.org/10.1186/s12885-026-16247-0)  \nRESEARCH Open Access  \nIsatin-mediated inhibition of the PI3K/AKT/ EMT signaling axis confers antitumor efficacy in Ehrlich solid carcinoma-bearing mice  \nHeba Effat 1*, Marwa A. Ibrahim2, Rehab S. Abohashem3,4, Yasmin M. Attia5 and Fatma M. Abdelwahed 1*  \nAbstract  \nDespite advances, detailed insight into cancer’s biological mechanisms remains needed. Isatin, an indole-1 H-2,3-dione, is an attractive agent for new drug discovery. Here, the anticancer efficacy and potential toxicity of isatin in combination with doxorubicin (Dox) in a mouse Ehrlich solid carcinoma (ESC) model were examined by modulating the PI3K/AKT/EMT pathway. Five groups of fifty female mice were prepared: negative control, positive ESC-bearing mice, isatin-treated ESC group, Dox-treated ESC group, and isatin and Dox combination-treated ESC group. Treatments began after tumor formation. Inflammatory markers, kidney and liver enzyme activities, and EMT markers levels (vimentin and E-cadherin) were assessed by ELISA. HIF 1 α, NF-κB, PI3K, AKT, MMP2, and MMP9 gene expression was evaluated using qRT-PCR. Protein expression of MMP-9 and E-cadherin was assessed by IHC. Compared with the positive control, the combined treatment reduced tumor growth by 51% . Additionally, combined treatment showed a significant increase in the amount of necrotic tissue. Mechanistically, isatin exerted its therapeutic effect by increasing anti-inflammatory (IL-10) cytokine levels and suppressing pro-inflammatory (IL-6) cytokine levels, along with reductions in HIF-1α, NF-κB, PI3K, AKT, MMP2, and MMP9 mRNA levels. Also, a combined group of isatin and Dox showed reduced vimentin levels and elevated E-cadherin levels by ELISA. Coadministration of isatin and Dox significantly increased E-cadherin expression and attenuated MMP-9 expression compared with the untreated group, as assessed by IHC. Our results indicate that isatin, in combination with doxorubicin, exerts a synergistic anticancer effect against ESC, offering a promising therapeutic approach to enhance treatment efficacy.  \nKeywords Ehrlich solid carcinoma, Isatin, Dox, Anticancer, Inflammation, PI3k/AKT/EMT  \n*Correspondence:  \nHeba Effat [hebatullah.effat@nci.cu.edu.eg](hebatullah.effat@nci.cu.edu.eg)[ ](hebatullah.effat@nci.cu.edu.eg)Fatma M. Abdelwahed [fatma.abdelwahed@nci.cu.edu.eg](fatma.abdelwahed@nci.cu.edu.eg)  \n1Medical Biochemistry and Molecular Biology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt 2Medicinal and Aromatic Plants Department, Desert Research Center, Cairo, Egypt  \n3Hormones Department, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt  \n4Stem Cell Lab., Centre of Excellence for Advanced Sciences, National Research Centre, Giza, Egypt  \n5Pharmacology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Kasr El Aini Street, Fom El Khalig, Cairo 11796, Egypt  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permissi","cbCainySBCxF04zO","https://ap.wps.com/l/cbCainySBCxF04zO","pdf",3591341,15,"English","# Abstract\n# Introduction\n## Background on cancer chemotherapy and mechanisms\n## Ehrlich tumor model and relevance\n## Doxorubicin as established chemotherapeutic\n# Experimental approach (as described in Abstract)\n## Animal groups and treatments\n## Biomarker assessment (ELISA, qRT-PCR, IHC)\n# Results and mechanistic findings\n## Tumor growth and necrosis\n## Inflammation and signaling pathway modulation\n## EMT marker changes","[{\"question\":\"What cancer model was used to test isatin and doxorubicin?\",\"answer\":\"The study used Ehrlich solid carcinoma-bearing mice (ESC model) to evaluate anticancer efficacy after tumor formation.\"},{\"question\":\"How did the isatin–doxorubicin combination affect tumor outcomes?\",\"answer\":\"Compared with the positive control, the combined treatment reduced tumor growth by 51% and increased the amount of necrotic tissue.\"},{\"question\":\"Which signaling and EMT-related markers were monitored, and what changed?\",\"answer\":\"The work assessed PI3K/AKT/EMT pathway components and EMT markers, reporting reduced HIF-1α, NF-κB, PI3K, AKT, MMP2, MMP9 and lower vimentin with elevated E-cadherin, consistent with EMT suppression.\"}]","Isatin-mediated inhibition of the PI3K/AKT/EMT signaling axis confers antitumor efficacy in Ehrlich solid carcinoma-bearing mice | PDF",1790057894,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f5b3686c61fc339bfd50d9eb950462fe.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8b3e3dd56a42c99cadd5b6ad9429fa19.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb2d0047795b0132d0d4df8955088e70.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e23e0cdbc5dfecef760f13cb2ffd7460.webp",980,1306]